ArticleCancer medicine2025
Bioinformatics Analysis and Experimental Validation of ASF1B in Breast Tumors.
Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Tetrandrine-based in situ vaccination via multifunctional Mn²⁺-hyaluronic acid hydrogel loading gelatinase-responsive nanoparticles.Journal of nanobiotechnology · 2026Article
- Bioinformatics Analysis and Experimental Validation of ASF1B in Breast Tumors.Cancer medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveTo investigate the association between ASF1B expression and pathological characteristics of breast cancer, and to further explore its role in tumor progression and the immune microenvironment, thereby evaluating its potential as a therapeutic target.
methodsASF1B expression in breast cancer was analyzed using the GEPIA2 and BEST databases. Its association with patient prognosis was assessed using Kaplan-Meier survival analysis. Protein co-expression networks were constructed using GeneMANIA. The correlation between ASF1B expression and immune cell infiltration was evaluated through the TIMER platform. Experimental validation was performed using qPCR and immunohistochemistry (IHC) on 67 breast cancer tissue samples.
resultsASF1B expression was significantly elevated in breast cancer tissues compared to normal tissues (p < 0.05). High ASF1B expression was associated with reduced overall and recurrence-free survival (p < 0.05). Protein interaction analysis revealed that ASF1B was strongly linked to proteins involved in DNA replication, cell cycle progression, and chromatin remodeling. Immune analysis indicated positive correlations with B cells, neutrophils, and dendritic cells and a negative correlation with macrophage infiltration (p < 0.05). Clinical data further showed that high ASF1B expression was significantly associated with HER2-positive breast cancer (p = 0.026).
conclusionASF1B is highly expressed in breast cancer and correlates with poor prognosis and immune cell infiltration. It may serve as a potential prognostic biomarker and therapeutic target in breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.